Disability progression in relapsing MS tends to follow one of four distinct patterns, according to a new study.

The drug, tolebrutinib, delayed disability progression by 31% in people with a type of MS called non-relapsing secondary progressive multiple sclerosis, researchers reported in the New England Journal ...

Panelists discuss how progression independent of relapse activity (PIRA) represents a distinct pathological process involving smoldering inflammation and neurodegeneration that drives disability in ...

Disease-modifying therapies for MS that prevent brain volume loss are linked to reduced long-term disability, new data show.

The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS). The HERCULES ...

Racial and ethnic differences in the severity, prognosis, and mortality of multiple sclerosis (MS) have been the focus of intensifying research over the last decade, and emerging evidence suggests ...

Tolebrutinib delayed disability progression by 31% in people with secondary progressive multiple sclerosis No drugs are currently approved to treat this type of MS WEDNESDAY, April 9, 2025 (HealthDay ...

Higher consumption of oily fish such as tuna and salmon or lean fish like cod and perch is associated with a reduced risk for disability progression in patients with multiple sclerosis (MS), a new ...

In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before disability worsened between people taking certain medications and those not ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. An oral brain-penetrant therapeutic delayed the onset of ...

Physical activity was associated with a lower risk of disability progression in multiple sclerosis (MS), longitudinal data showed. Compared with low physical activity, the risk of confirmed disability ...

October 12, 2012 (Lyon, France) — Final results of a phase 3 trial comparing 2 doses of teriflunomide (Aubagio, Genzyme/Sanofi), 14 mg/d and 7 mg/d, vs placebo in patients with relapsing multiple ...